Results 91 to 100 of about 21,498,068 (261)
Mycobacterial 3‐methylcrotonyl‐CoA carboxylase uses a mobile biotin‐carrying domain to shuttle a carboxyl group between two catalytic sites, enabling carboxylation of 3‐methylcrotonyl‐CoA during leucine breakdown. Cryo‐electron microscopy captures the carrier at both sites and reveals an inward loop movement that may prevent futile rebinding to the ...
Ajit Yadav +2 more
wiley +1 more source
WHO Drug Information 2023, vol. 37, 3 [full issue]
[343] p.Ensuring the quality, safety and consistent nomenclature of pharmaceutical substances is a central component of global health regulation and access to medicines.
World Health Organization
core
Synechocystis strains deficient in succinate dehydrogenase (SDH) secrete more succinate than the WT under dark anaerobic conditions, supporting that SDH then primarily acts as SDH, not as a fumarate reductase. L‐aspartate oxidase (Laspo) from Synechocystis is functional under anaerobic conditions, reducing fumarate to succinate.
Kateryna Kukil +3 more
wiley +1 more source
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise +5 more
wiley +1 more source
A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos +9 more
wiley +1 more source
‘Civil society involvement in drug policy’ webinar.
On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...
core
WHO Drug Information 2023, vol. 37, 1 [full issue]
263 p.Ensuring the quality, safety and consistent identification of pharmaceutical substances is a central component of effective medicines regulation and public health protection.
World Health Organization
core
Smaller is better: nanobodies meet NMR
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
WHO Drug Information 2024, vol. 38, 1 [full issue]
234 p.Ensuring consistent global standards for medicines classification, nomenclature and quality is fundamental to regulatory harmonization and the safe use of pharmaceutical substances.
World Health Organization
core
Training toolkit on drug policy advocacy.
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...
core

